In a study on obese patients with COPD, authors examined the effect of the GLP-1 RA liraglutide (3.0 mg) for 40 weeks on pulmonary measures and the clinical impact of COPD
Even bodyweight exercises help
Concerns about the potential association between certain diabetes medications and cardiovascular disease meant that in 2010 the FDA approved liraglutide on condition that Novo Nordisk conduct a post-marketing study to evaluate the drug's effect on the incidence of major cardiovascular events (Nielsen, DeChiaro, Goldman)
Health Canada said evaluating them is complex because Novo Nordisk's products were developed using biological processes while some generic versions are made using chemical means
Changes in density following the use of GLP-1 agonists may obfuscate previously identified and may create a clinical dilemma in the setting of actionable BI-RADS findings
FDA inspections of certain foreign active pharmaceutical ingredient (API) facilities supplying the compounded market revealed manufacturing deficiencies, including equipment residue, water leaks, and sterile-processing failures
